CHARMD

TOP

• Short name: Antimicrob Agents Chemother
• References:
• -Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017).
• -Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012).
• -Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013).
• -Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. (Jan 2011).
• -Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009).
• -Emergence of multiple human cytomegalovirus ganciclovir-resistant mutants with deletions and substitutions within the UL97 gene in a patient with severe combined immunodeficiency. (Feb 2001).
• -Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014).
• -Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007).
• -Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014).
• -Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014).
• -Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999).
• -Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. (Jan 2007).
• -New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018).
• -Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016).
• -Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015).
• -Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011).
• -Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010).
• -Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus. (Jul 2013).
• -Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. (Oct 2001).

Mutations: